Built on the groundbreaking immuno-neurology research of our scientific founder, Dr. Edgar Engleman, and his team at Stanford, Tranquis is focused on the discovery and development of novel small molecules designed to target and normalize myeloid immune cell dysfunction linked to immune-mediated and mitochondrial diseases. Our goal is to revolutionize and advance the management of a broad range of neurodegenerative and non-CNS disorders by modifying underlying disease, reducing disease burden, and making a meaningful difference in the lives of patients and families.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):